Study of an ALK-targeted drug for ALK-positive lung cancer
Treatments studied
Part of Cancer clinical trials.
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+) or, for a specific group, at least 12 years old and over 40 kg
- Your cancer has an ALK gene change (an ALK rearrangement or an activating ALK mutation) proven by an approved test
- For Phase 2 (most groups), your cancer is ALK-rearranged non-small cell lung cancer, or for the 2f group it can be another solid tumor
- Your cancer should be measurable (visible/trackable) on scans, depending on the phase of the trial
- Your organs and blood counts (bone marrow) must be strong enough for treatment
- Your cancer should not have another known major driver mutation besides ALK
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program lets people with advanced ALK-positive cancer (like lung cancer) who have run out of standard options try an investigational drug called neladalkib through an expanded access program, not a clinical trial.
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This study tests a new drug called ALK202, given with other medicines, to see if it is safe and works for people with non-small cell lung cancer. It targets certain proteins on cancer cells, and doctors will check your tumor for those markers to see if you might benefit.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
Hear when a new Locally Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.